New drug duo shows promise for tough breast cancers
NCT ID NCT05445908
First seen Nov 17, 2025 · Last updated Jun 12, 2026 · Updated 27 times
Summary
This study tests a new drug (SKB264) alone or with another drug (KL-A167) in people with advanced HER2-negative breast cancer that hasn't been treated yet. The goal is to see if the combination is safe and shrinks tumors. About 175 adults with triple-negative or HR+/HER2- breast cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER AND HR+/HER2- BC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.